CHRISTOPHER WIEGAND: Open Payments
NPI 1780767137 · TUSCON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$808 in 38 payments from 12 companies in 2025. Trend: 2023 $503 · 2024 $796 · 2025 $808
Food & beverage: $808
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $166 |
| Neurocrine BioSciences, Inc. | 3 | $103 |
| Lundbeck LLC | 5 | $101 |
| ABBVIE INC. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $25 |
Products named: INGREZZA, REXULTI, VRAYLAR, SPRAVATO, CAPLYTA, INVEGA SUSTENNA, FANAPT, AUSTEDO XR.
Industry payments across AZ — which companies pay providers there.
